{"@id":"https://bioecon.ru/technology/gene-therapy-ageing-targets/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://bioecon.ru/technology/gene-therapy-ageing-targets/","json":"https://bioecon.ru/api/v1/technology/gene-therapy-ageing-targets/index.json"},"id":"gene-therapy-ageing-targets","industries":["longevity"],"lang":"ru","links":{"industries":["https://bioecon.ru/industries/longevity/"],"suppliers":["https://bioecon.ru/companies/minicircle/","https://bioecon.ru/companies/bioviva/","https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/cryoport-systems/","https://bioecon.ru/companies/astrazeneca/","https://bioecon.ru/companies/kheiron-biotech/","https://bioecon.ru/companies/cibus/","https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/chenot/","https://bioecon.ru/companies/absolute/"]},"maturity":2,"name":"Генная терапия мишеней старения (клото, теломераза, фоллистатин)","regions":["us"],"risk":"high","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-09","entity":"cell.com","kind":"research","urls":["https://www.cell.com/trends/molecular-medicine/pdf/S1471-4914(26)00116-4.pdf"]},{"date":"2026-11-09","entity":"benjaminfranklininstitute.org","kind":"web","urls":["https://benjaminfranklininstitute.org/unapproved-gene-therapy-for-boosting-longevity-is-set-to-go-on-sale/"]},{"date":"2026-11-09","entity":"wired.com","kind":"web","urls":["https://www.wired.com/story/bioviva-gene-therapies-liz-parrish-longevity/"]},{"date":"2026-11-09","entity":"minicircle.io","kind":"web","urls":["https://minicircle.io/wp-content/uploads/2024/04/fstpreprint.pdf"]},{"date":"2026-11-09","entity":"pmc.ncbi.nlm.nih.gov","kind":"research","urls":["https://pmc.ncbi.nlm.nih.gov/articles/PMC10017145/"]}],"stages":[{"n":1,"title":"Выбор гена"},{"n":2,"title":"Доставка"},{"n":3,"title":"Безопасность"}],"summary":"Экспериментально: AAV- и плазмидные генные терапии генов долголетия на фазе 1 без опубликованных данных об эффективности, а часть продаётся за рубежом вне одобрения FDA; высокий риск, тема спорная.","url":"/technology/gene-therapy-ageing-targets/","verified":"2026-11-09"}